Senzime announces the nomination committee for the AGM 2017

Uppsala, January 20, 2017. Senzime announces the nomination committee for the AGM 2017.

The Nomination Committee, which is appointed in accordance with the principles adopted at the AGM 2016 consists of:

·         Terry Cross

·         Sorin Brull

·         Adam Dahlberg

·         Ulf Lindskog

·         Philip Siberg

Chairman of the Nomination Committee is Philip Siberg.

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email:


About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI)

Explore our patient monitoring solutions

Get product details

How can Senzime’s products help to eliminate in-hospital complications?
Contact us to discuss your needs or schedule a product demo.